Combination of Steven-Johnson syndrome and neuroleptic malignant syndrome following carbamazepine therapy: A rare occurrence

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Sharma, Bhawna ^a   Sannegowda, Raghavendra Bakki ^a   Gandhi, Pankaj ^a   Dubey, Parul ^b   Panagariya, Ashok ^a  

^a SMS MEDICAL COLLEGE   (India)

^b Manipal Hospitals   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BROMOCRIPTINE; C REACTIVE PROTEIN; CARBAMAZEPINE; CREATINE KINASE; ETIRACETAM; INFUSION FLUID; IRON;

ADOLESCENT; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE FLUCTUATION; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; FEVER; FLUID THERAPY; HEART RATE; HUMAN; HYDRATION; HYPOCALCEMIA; IRON BLOOD LEVEL; LEUKOCYTOSIS; MACULOPAPULAR RASH; MALE; MOUTH ULCER; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; RIGIDITY; SEIZURE; STEVENS JOHNSON SYNDROME; SWEATING; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

EID: 84880070622     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-008908     Document Type: Article

References (26)

1. Coleman A, Trappler B. Stevens-Johnson syndrome following treatment with carbamazepine for a mood disorder. Jefferson J Psychiatry 1996;13, Article 8:48-53.
2. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7:803-13.
3. Frisch PO, Ruiz-Maldonado R. Erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. Fitzpatrick's dermatology in general medicine. 6th edn. New York: McGraw-Hill, 2003:543-57.
4. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
5. Devi K, George S, Criton S, et al. Carbamazepine - The commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol 2005;71:325-8. (Pubitemid 41376754)
6. Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011;39:1521-32.
7. Wei CY, Chung WH, Haung HW, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012;129:1562- 9.
8. Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin Drug Saf 2010;9:15-21.
9. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2012;8:5.
10. Panagariya A, Sharma B, Singh R, et al. The neuroleptic malignant syndrome: a report of 14 cases from North India. Neurol India 2007;55:166-8. (Pubitemid 46918490)
11. Kurien T, Rajeev KK, Abraham OC. Management of neuroleptic malignant syndrome - a series of eight cases. J Assoc Physicians India 1993;41:91-3.
12. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology 1981;31:132-7. (Pubitemid 11137588)
13. Anglin RE, Rosebush PI, Mazurek MF. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CMAJ. 2010;182:E834-8.
14. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;328:149-51.
15. Ben-Shachar D, Finberg JPM, Youdim MBH. Effect of iron chelators on dopamine D2 receptors. J Neurochem 1985;45:999-1005. (Pubitemid 16258140)
16. Guzofski S, Peralta R. Neuroleptic malignant syndrome, with attention to its occurrence with atypical antipsychotic medication: a review. Jefferson J Psychiatry 2006;20:53-6.
17. Adnet P, Lestavel P, Krivosic R. Horber-Neuroleptic malignant syndrome. Br J Anaesthesia 1985;1:129-35.
18. Caroff SN, Mann SC. Neuroleptic malignant syndrome" Psychopharmacol Bull 1988;24:25-9.
19. Mason PJ, Morris VA, BalcezaK TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 2000;79:201-9. (Pubitemid 30616969)
20. Janati AB, ALGhasab N, Osman A. Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline. Case Rep Neurol Med 2012;2012:1-3.
21. Thomas P, Maron M, Rascle C, et al. Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol Psychiatry 1998;43:303-5. (Pubitemid 28085678)
22. Woo Benjamin KP, Obrocea GV. Atypical case of neuroleptic malignant syndrome caused by olanzapine and carbamazepine. Psychiatry (Edgmont) 2005;2:23-4.
23. Nisijima K, Kusakabe Y, Ohtuka K, et al. Addition of carbamazepine to long-term treatment with neuroleptics may induce neuroleptic malignant syndrome. Biol Psychiatry 1998;44:930-1.
24. Dalkin T, Lee AS. Carbamazepine and forme fruste neuroleptic malignant syndrome. Br J Psychiatry 1990;157:437-8. (Pubitemid 20285460)
25. O Griofa FM, Voris JC. Neuroleptic malignant syndrome associated with carbamazepine. South Med J 1991;84:1378-80.
26. Muhammed K, Raman P. Simultaneous occurrence of toxic epidermal necrolysis and neuroleptic malignant syndrome. Indian J Dermatol, Venereol Leprol 2005;71:270-2. (Pubitemid 41191366)